Effects of Tesamorelin on Hepatic Fat in HIV Patients: A Randomized Placebo-Controlled Trial
Background: Hepatic fat is often increased in HIV-infected patients with abdominal fat accumulation and may contribute to metabolic abnormalities. Currently, no strategies exist to reduce fat in this critical depot among HIV-infected patients. Tesamorelin, a growth hormone releasing hormone analogue, is FDA-approved for reduction of visceral fat in HIV, but its effects on hepatic fat…